Business Wire

CARBIOS

24.6.2021 07:02:13 CEST | Business Wire | Press release

Share
Global Consumer Brands Unveil World’s First Enzymatically Recycled Bottles

The promise of endlessly recycled PET plastic is one step closer today, as the Consortium – Carbios, L’Oréal, Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe – announces the successful production of the world’s first food-grade PET plastic bottles produced entirely from enzymatically recycled plastic.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005867/en/

Each Consortium company has successfully manufactured sample bottles – based on Carbios’ enzymatic PET recycling technology – for some of their leading products including: Biotherm®, Perrier®, Pepsi Max®** and Orangina®.

Today’s announcement is the culmination of nearly 10 years’ research and development by Carbios to create a new process and supercharge an enzyme naturally occurring in compost heaps that normally breaks down leaf membranes of dead plants. By adapting this enzyme, Carbios has fine-tuned the technology and optimized this enzyme to break down any kind of PET plastic (regardless of color or complexity) into its building blocks, which can then be turned back into like-new, virgin-quality plastic.

Carbios’ patented enzymatic PET recycling process enables a wide variety of PET plastics to be recycled into virgin quality, food grade rPET. PET plastics that would otherwise go to waste or be incinerated, can now be brought back into a continuous circular system of recycling. And this can be achieved at high speed – breaking down 97% of plastic in just 16 hours – 10,000 times more efficient than any biological plastic recycling trial to date (peer-reviewed article in Nature ).

Together, these brands will work to scale this innovation to help meet the global demand for sustainable packaging solutions. In September 2021, Carbios will break ground on a demonstration plant, before launching a 40,000 tons capacity industrial facility, by 2025.

Commenting on the announcement, Carbios’ CEO Jean Claude Lumaret commented: “In a world first, we have created food-grade clear bottles from enzymatically recycled colored and complex plastic with identical properties to virgin PET, and in partnership with the Consortium, we have proved the viability of the technology with the world’s leading brands. This is a truly transformational innovation that could finally fully close the loop on PET plastic supply globally, so that it never becomes waste.”

Jacques Playe, L’Oréal’s Global Head of Packaging and Product Development added: “We have been working with Carbios since 2017 to develop this first bottle made from PET derived from enzymatic recycling technology, an alternative to mechanical recycling. We are pleased to announce today the feasibility of these bottles in a pilot phase and are delighted to be in a position to create the packaging of the future with our partners. This is a promising innovation for the years to come that demonstrates our commitment to bring to market more environmentally friendly packaging and which is part of a circularity initiative begun more than 15 years ago”.

Jean-Francois Briois, Head of Packaging Material Science and Environmental Sustainability Nestlé Waters global R&D added: “It is very exciting to see that the quality of the prototype bottles made from colored recycled PET materials is virtually identical to clear virgin PET. When we reach industrial scale, this enzymatic recycling technology will enable us to produce high-quality rPET bottles and help Nestlé Waters in our journey to boost the circular economy and reduce the use of virgin plastics.”

Ron Khan, Global VP of Packaging, Beverages, PepsiCo added: “PepsiCo is committed to building a circular economy to achieve our vision that packaging never becomes waste. We are dedicated to reducing the virgin plastic we use and with the breakthrough Carbios enzymatic recycling technology, we can help keep valuable material in the circular economy, reduce waste and take another step toward a truly closed loop system.”

Roberto Vanin, Chief R&D Officer, Suntory Beverage & Food Europe, added: “The global issue of plastic waste requires transformational thinking, creative partnerships and innovative brands coming together to seek out new solutions. Continued investment in new ways of tackling waste and creating true circularity such as this ground-breaking technology from Carbios will be key to Suntory Beverage & Food Europe achieving its 100% sustainable plastic ambition.”

Enzymatic recycling overcomes the issue of degradation in conventional recycling and can be used on any type of PET plastic. Because Carbios’ recycling process works under mild conditions, it could also lower the carbon footprint of PET waste treatment by saving 30% of CO2 emissions compared to a conventional end of life mix of incineration and landfill, taking virgin PET production substitution into account.***

The successful completion of these initial food-grade bottles is a major milestone in the Consortium’s validation of Carbios’ technology. This partnership is part of a growing trend amongst brands to collaborate across industries to tackle these global challenges, working towards a world of circularity, where we limit the production of virgin plastic.

Carbios will license its technology to PET manufacturers worldwide, accelerating the global adoption of enzymatic recycling for all kinds of PET based products.

Notes to Editors

To book interviews or to request further information or images, please contact lon-carbios@ketchum.com

** Pepsi Max® also known as Pepsi Black or Pepsi Zero Sugar in other global markets.

*** Preliminary Life Cycle Assessment of Carbios PET recycling process, 2021

About Enzymatic Recycling

Around 70 million tons of PET plastic is manufactured globally every year – equal to around 20% of all plastic – but through repeated conventional thermomechanical processes, the plastic used in packaging is degraded over time and requires new virgin plastic to retain its quality.

Carbios has successfully hyper-charged a naturally occurring enzyme from compost heaps that breaks down leaf membranes of dead plants. PET plastic is made from a string of building blocks also called monomers and this optimized enzyme is super-efficient at cutting the PET plastic into these building blocks: terephthalic acid and ethylene glycol. Those monomers can then be recombined to recreate the PET polymer, at food grade quality, in an infinite, virgin-quality loop.

About Carbios

Carbios, a green biotech company, develops biological and innovative processes to revolutionize the end of life of plastics and textiles. Through its unique approach of combining enzymes and plastics, Carbios aims to address new consumer expectations and the challenges of a broader energy transition by taking up a major challenge of our time: plastic and textile pollution. Carbios was named one of the World Economic Forum’s Technology Pioneers of 2021 .

Carbios and L’Oréal founded the Consortium in 2017 and were joined in 2019 by Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe.

For more information, please visit http://www.carbios.com/en/

For more information, please visit:

https://www.suntorybeverageandfood-europe.com

https://www.linkedin.com/company/suntory-beverage-&-food-europe-limited/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye